Compare Global E Online Ltd (GLBE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Global E Online Ltd trades at $38.51 (market cap $6.55B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.75B). The key difference: Global E Online Ltd is far larger — about 3.7× Recursion Pharmaceuticals Inc's market cap, and Global E Online Ltd is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| GLBE | RXRX | |
|---|---|---|
Market Cap | $6.55B | $1.75B |
Sector | Technology | Health |
52-Week High | $41.59 | $6.79 |
52-Week Low | $27.54 | $2.84 |
Enterprise Value | $6.02B | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $38.70, down 0.13% on the day, with a strong bullish technical signal from moving averages. The company reported Q1 2026 revenue growth of 33% year-over-year and raised full-year 2026 guidance, while maintaining a high P/E ratio of 58.18. Recent acquisition of Passport aims to enhance logistics capabilities, supporting future growth in cross-border e-commerce.
Outlook remains positive with 100% analyst buy ratings and a consensus price target of $38.00, though high valuation and recent insider sales present risks. Earnings momentum and strategic expansions provide upside potential, but investors should monitor competitive pressures and execution of growth initiatives.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
